High-altitude cerebral edema: its own entity or end-stage acute mountain sickness?

J Appl Physiol (1985)

Division of Performance Physiology & Prevention, Department of Sport Science, University of Innsbruck, Innsbruck, Austria.

Published: July 2021

High-altitude cerebral edema (HACE) and acute mountain sickness (AMS) are neuropathologies associated with rapid exposure to hypoxia. However, speculation remains regarding the exact etiology of both HACE and AMS and whether they share a common mechanistic pathology. This review outlines the basic principles of HACE development, highlighting how edema could develop from ) a progression from cytotoxic swelling to ionic edema or ) permeation of the blood brain barrier (BBB) with or without ionic edema. Thereafter, discussion turns to the available neuroimaging literature in the context of cytotoxic, ionic, or vasogenic edema in both HACE and AMS. Although HACE is clearly caused by an increase in brain water of ionic and/or vasogenic origin, there is very little evidence that this type of edema is present when AMS develops. However, cerebral vasodilation, increased intracranial blood volume, and concomitant intracranial fluid shifts from the extracellular to the intracellular space, as interpreted from changes in diffusion indices within white matter, are observed consistently in persons acutely exposed to hypoxia and with AMS. Therefore, herein we explore the idea that intracellular swelling occurs alongside AMS, and is a critical precursor to extracellular ionic edema formation. We propose that this process produces a subtle modulation of the BBB, which either together with or independent of vasogenic edema provides a transvascular segue from the end-stage of AMS to HACE. Ultimately, this review seeks to shed light on the possible processes underlying HACE pathophysiology, and thus highlights potential avenues for future prevention and treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1152/japplphysiol.00861.2019DOI Listing

Publication Analysis

Top Keywords

ionic edema
12
edema
9
high-altitude cerebral
8
cerebral edema
8
acute mountain
8
edema hace
8
hace ams
8
vasogenic edema
8
ams hace
8
hace
7

Similar Publications

This research work was designed to develop efficient Diosgenin (DGN) loaded biodegradable nanoparticles (DGN-NPs) for treating rheumatoid arthritis. The DGN-NPs were synthesized by ionic-gelation method using chitosan as a biodegradable polymer and in-vitro release study was performed followed by kinetics study. DGN-NPs had an average size of 290 nm, zeta potential of +11.

View Article and Find Full Text PDF

Pericardial edema - fluid accumulation within the pericardium - is a frequently observed malformation in zebrafish embryo-based chemical toxicity screens. We recently discovered that the severity of triphenyl phosphate (TPHP)-induced pericardial edema was dependent on the ionic strength of exposure media. TPHP is an aryl phosphate ester (APE) widely used as a plasticizer and flame retardant.

View Article and Find Full Text PDF

Injectable nanogels to improve triamcinolone acetonide delivery and toxicity on the treatment of eye diseases.

J Biomater Appl

August 2024

Faculty of Medicine, Advanced Technologies Application and Research Center, Ankara Yıldırım Beyazıt University, Ankara, Turkey.

Triamcinolone acetonide (TA) is a corticosteroid, and widely used in the treatment of eye diseases such as macular edema, proliferative vitreoretinopathy, and chronic uveitis. It's also used in diseases such as osteoarthritis and rheumatoid arthritis. Despite the width of its usage, it has toxicity in the eye.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICI) are increasingly used in the first-line treatment of malignant tumors. There is increasing recognition of their cardiotoxicity and, in particular, their potential to lead to myocarditis. Cardiovascular magnetic resonance (CMR) can quantify pathological changes, such as myocardial edema and fibrosis.

View Article and Find Full Text PDF

Chronic thromboembolic pulmonary hypertension (CTEPH) is classified as group IV pulmonary hypertension, characterized by thrombotic occlusion of the pulmonary arteries leading to vascular stenosis or obstruction, progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and eventual right heart failure. Unlike other types of pulmonary hypertension, the prognosis of CTEPH can be significantly improved by surgery, vascular intervention, and/or targeted drug therapy. Pulmonary endarterectomy (PEA) is the preferred treatment of choice for CTEPH.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!